CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation
- PMID: 10384105
CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation
Abstract
CD8+ T cells stimulated in vitro with anti-TCR mAb and B7-1 or ICAM-1 produce IL-2 and clonally expand. Effector function is acquired within 3 days, but proliferation ceases and the cells begin to die by apoptosis. Stimulation in vivo with B7-1-expressing allogeneic tumor results in the same sequence of events with a comparable time course. In both cases, the cells become anergic within 3 or 4 days of responding; they can no longer respond by producing IL-2 and proliferating, but can still be stimulated to proliferate in response to exogenous IL-2. This activation-induced nonresponsiveness (AINR) is not simply a consequence of ongoing cell death; cytokines that promote survival (IL-7 or IFN-alpha) or proliferation (human IL-2) do not restore the ability to produce IL-2 in response to costimulation. Although similar to the anergy described for CD4+ T cell clones, AINR differs in that it results from an initial stimulation with both signal 1 and signal 2. AINR appears to be an aspect of the normal differentiation of fully stimulated CD8+ T cells. It is probably important in regulating CTL responses; it limits the initial T helper-independent response and converts it to a response that requires T cell help to be sustained and further expanded. When the initial helper-independent response is not sufficient to clear Ag, and if help is not available, AINR likely results in tolerance to the Ag.
Similar articles
-
Critical role of costimulation in the activation of naive antigen-specific TCR transgenic CD8+ T cells in vitro.J Immunol. 1999 Aug 1;163(3):1298-305. J Immunol. 1999. PMID: 10415027
-
Signaling alterations in activation-induced nonresponsive CD8 T cells.J Immunol. 2001 Aug 15;167(4):2040-8. doi: 10.4049/jimmunol.167.4.2040. J Immunol. 2001. PMID: 11489986
-
Functional consequences of costimulation by ICAM-1 on IL-2 gene expression and T cell activation.J Immunol. 1998 Apr 1;160(7):3259-68. J Immunol. 1998. PMID: 9531282
-
Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors.Semin Cancer Biol. 2007 Aug;17(4):299-308. doi: 10.1016/j.semcancer.2007.06.008. Epub 2007 Jun 23. Semin Cancer Biol. 2007. PMID: 17656106 Free PMC article. Review.
-
T cell anergy.Annu Rev Immunol. 2003;21:305-34. doi: 10.1146/annurev.immunol.21.120601.141110. Epub 2001 Dec 19. Annu Rev Immunol. 2003. PMID: 12471050 Review.
Cited by
-
Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.J Immunother. 2008 Nov-Dec;31(9):906-20. doi: 10.1097/CJI.0b013e318189f155. J Immunother. 2008. PMID: 18832997 Free PMC article.
-
Anti-viral CD8 T cells and the cytokines that they love.Virology. 2013 Jan 5;435(1):157-69. doi: 10.1016/j.virol.2012.09.012. Virology. 2013. PMID: 23217625 Free PMC article. Review.
-
Ikaros imposes a barrier to CD8+ T cell differentiation by restricting autocrine IL-2 production.J Immunol. 2014 Jun 1;192(11):5118-29. doi: 10.4049/jimmunol.1301992. Epub 2014 Apr 28. J Immunol. 2014. PMID: 24778448 Free PMC article.
-
4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.J Immunol. 2007 Oct 1;179(7):4910-8. doi: 10.4049/jimmunol.179.7.4910. J Immunol. 2007. PMID: 17878391 Free PMC article.
-
Cognate antigen engagement on parenchymal cells stimulates CD8+ T cell proliferation in situ.Nat Commun. 2017 Apr 12;8:14809. doi: 10.1038/ncomms14809. Nat Commun. 2017. PMID: 28401883 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous